CBIT: Comprehensive Behavioral Intervention for Tics

Sponsor
University of Miami (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05370391
Collaborator
(none)
200
1
1
16
12.5

Study Details

Study Description

Brief Summary

The purpose of this protocol is to examine treatment outcomes of youth receiving the Comprehensive Behavioral Intervention for Tics (CBIT) and better understand the predictors, moderators, mediators and/or mechanisms of change for this intervention.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Comprehensive Behavioral Intervention for Tics (CBIT)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Comprehensive Behavioral Intervention for Tics (CBIT) for Youth With Tics and Related Emotional Disorders
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Jan 1, 2024
Anticipated Study Completion Date :
Jan 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Comprehensive Behavioral Intervention for Tics (CBIT)

Experimental: Comprehensive Behavioral Intervention for Tics (CBIT) Group Participants in this group will receive the CBIT intervention for up to 6 weeks.

Behavioral: Comprehensive Behavioral Intervention for Tics (CBIT)
The CBIT (or CBIT-JR) intervention consists of a minimum of 6 sessions of 50-minutes each week in an individual or group setting.

Outcome Measures

Primary Outcome Measures

  1. Clinical Global Impression (CGI) - Severity Scale Scores [Up to 6 weeks from start of treatment]

    A single-item clinician-reported measure used to assess the severity of the youth's illness at the time of assessment. The CGI-S is rated on a 7-point scale ranging from 1 (slight psychiatric illness) to 7 (extremely severe psychiatric illness). Higher scores indicate greater symptom severity.

  2. Clinical Global Impression (CGI) - Improvement Scores [Up to 6 weeks from start of treatment]

    A single-item clinician-reported measure used to assess clinical changes in youth symptomology over the course of treatment. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved since the initiation of treatment) to 7 (very much worse since the initiation of treatment). Higher scores indicate greater symptom improvement since baseline

  3. Parent Tic Questionnaire (PTQ) [Up to 6 weeks from start of treatment]

    A 28-item parent-reported measure used to assess the frequency and intensity of different motor and vocal tic symptoms in youth. The PTQ evaluates tic frequency on a 4-point scale, ranging from 1 (constant) to 4 (weekly), and intensity on a 3-point scale, ranging from 1 (mild) to 3 (very noticeable). This is done for each presenting tic. Composite total scores on the PTQ range from 2-138. Higher summed composite score indicating more tics.

  4. Premonitory Urge Tic Scale (PUTS) [Up to 6 weeks from start of treatment]

    A 10-item self-reported measure that assess the severity of premonitory urges. The PUTS is rated on a 4-point scale ranging from 1 (not at all true) to 4 (very much true). Total scores range from 10-40 with higher scores indicating greater symptom severity.

  5. Youth Quality of Life (YQOL) Instrument - Short Form (SF) Scores [Up to 6 weeks from start of treatment]

    A 15-item self-reported measure of quality of life for youth ages 11-18. The YQOL-SF is rated on a 10-point scale from 0 (not at all) to 10 (very much). Scores range from 0 to 100, with higher scores indicating a higher quality of life.

  6. Yale Global Tic Severity Scale (YGTSS) - Total Tic Scores [Up to 6 weeks from start of treatment]

    The YGTSS is a clinician-rated interview assessing both motor and phonic tic symptoms across 5 domains: total number, frequency, intensity, complexity, and interference. Items from each domain for motor and phonic tics are summed to produce the YGTSS Total Tic Score, which ranges from 0-50. Higher scores on the YGTSS - Total Tic Score suggests greater tic severity.

  7. Yale Global Tic Severity Scale (YGTSS) - Total Motor Tic Scores [Up to 6 weeks from start of treatment]

    The YGTSS is a clinician-rated interview assessing both motor and phonic tic symptoms across 5 domains: total number, frequency, intensity, complexity, and interference. Items from each domain for motor tics are summed to produce the YGTSS Total Motor Tic Score, which ranges from 0-25. Higher scores on the YGTSS - Total Motor Score suggests greater motor tic severity.

  8. Yale Global Tic Severity Scale (YGTSS) - Total Phonic Tic Score [Up to 6 weeks from start of treatment]

    The YGTSS is a clinician-rated interview assessing both motor and phonic tic symptoms across 5 domains: total number, frequency, intensity, complexity, and interference. Items from each domain for phonic tics are summed to produce the YGTSS Total Phonic Tic Score, which ranges from 0-25. Higher scores on the YGTSS - Total Phonic Score suggests greater phonic tic severity.

  9. Yale Global Tic Severity Scale (YGTSS) - Overall Tic Related Impairment Scores [Up to 6 weeks from start of treatment]

    The YGTSS is a clinician-rated interview assessing both motor and phonic tic symptoms across 5 domains: total number, frequency, intensity, complexity, and interference. The YGTSS includes a separate impairment scale that reflects overall tic-related impairment, ranging from 0-50. Higher scores on this scale suggests greater tic impairment.

  10. Yale Global Tic Severity Scale (YGTSS) - Global Severity Score [Up to 6 weeks from start of treatment]

    The YGTSS is a clinician-rated interview assessing both motor and phonic tic symptoms across 5 domains: total number, frequency, intensity, complexity, and interference. The YGTSS includes a separate global severity scale that ranges from 0-100. Higher scores on this scale suggests greater global tic severity.

Secondary Outcome Measures

  1. Revised Children's Anxiety and Depression Scale - Child and Revised Parent Short (RCADS-25/RCADS-P-25) Scores [Up to 6 weeks from start of treatment]

    A 25-item self- and parent-reported scales measuring symptoms of anxiety and depression in youth. Items are rated on a 4-point scale from 1 (Never) to 4 (always) with scores ranging from 0 to 75. A score of 70 or higher indicates high severity, above clinical threshold.

  2. Tic Accommodation and Reactions Scale (TARS) Scores [Up to 6 weeks from start of treatment]

    A 35-item parent-reported measure used to assess reactions and consequences that occur in response to youth' tics. Items focus on events at home, in school, and in other public places. The TARS is rated on a 4-point scale from 0 (not at all in the past week) to 3 (many times in the past week). Scores range from 0 to 105, with higher scores indicating greater frequency of reaction and consequences in response to their child's tics.

Eligibility Criteria

Criteria

Ages Eligible for Study:
4 Years to 17 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion criteria

  • A current diagnosis of a Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 Tic disorder (e.g., Tourette's Disorder/syndrome, Persistent (Chronic) Motor or Vocal Tic Disorder, or Provisional Tic Disorder) or caregiver/youth report of clinically impairing tic symptoms

  • Ability for youth to speak/read English sufficiently

  • At least one parent/caregiver available to sign study consent forms, remain present during assessments, and fill out study questionnaires in English.

Exclusion criteria

  • A current diagnosis of psychosis, bipolar disorder, intellectual disability, acute suicidality, alcohol/substance dependence, or eating disorder.

  • Youth currently receiving psychotherapy elsewhere and/or have previously received CBIT.

  • Currently suicidal or who have engaged in suicidal behaviors within the past 6 months will be excluded

  • Youth currently taking psychotropic medication for a co-morbid psychiatric illness will be included without a wash-out period (to not delay treatment).

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Miami Coral Gables Florida United States 33124

Sponsors and Collaborators

  • University of Miami

Investigators

  • Study Director: Jill Ehrenreich-May, Ph.D., University of Miami

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jill May Ehrenreich, Professor, Department of Psychology, University of Miami
ClinicalTrials.gov Identifier:
NCT05370391
Other Study ID Numbers:
  • 20210853
First Posted:
May 11, 2022
Last Update Posted:
Jul 13, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 13, 2022